Europe Rabies Vaccine Market Size, Share & Trends Analysis Report By Prophylaxis Type (Post-exposure Prophylaxis, and Pre-exposure prophylaxis), By End User, By Application (Human, and Animal), By Product Type, By Country and Growth Forecast, 2023 - 2030

The Europe Rabies Vaccine Market would witness market growth of 4.1% CAGR during the forecast period (2023-2030).

The Germany market dominated the Europe Rabies Vaccine Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $101 Million by 2030. The UK market is exhibiting a CAGR of 3.2% during (2023 - 2030). Additionally, The France market would experience a CAGR of 4.9% during (2023 - 2030).



Professionals working in high-risk occupations, such as wildlife researchers, animal handlers, and veterinarians, may receive these vaccines to mitigate the risk of exposure during their work. This targeted vaccination strategy helps protect individuals regularly in close contact with animals, who may be more likely to encounter the rabies virus. These vaccines are crucial in emergency response situations, such as outbreaks or clusters of rabies cases.

Furthermore, dogs are the primary reservoirs and transmitters of the rabies virus to humans. Unvaccinated dogs carry a considerable risk of rabies transmission through bites in regions where the disease is endemic. The prevalence of dog bites, especially in areas with a high population of stray or unvaccinated dogs, underscores the urgent need for effective rabies vaccination programs.

Rabies is a zoonotic disease that threatens public health in France. The occurrence of rabies cases prompts public health authorities to implement preventive measures, including the vaccination of domestic animals and public awareness campaigns to reduce the risk of human exposure in France. Like many European countries, France has legal requirements for rabies vaccination of domestic animals, particularly dogs and cats. Veterinarians are pivotal in recommending and administering these vaccines to domestic animals in France. The increased incidence of rabies cases may lead to heightened awareness among pet owners, who are more likely to follow veterinary recommendations for vaccination in France. Thus, all these factors will uplift the regional market’s expansion in the coming years.

Based on Prophylaxis Type, the market is segmented into Post-exposure Prophylaxis, and Pre-exposure prophylaxis. Based on End User, the market is segmented into Hospitals, Veterinary Clinics, and Others. Based on Application, the market is segmented into Human, and Animal. Based on Product Type, the market is segmented into Chick Embryo Cells Rabies Vaccine, Human Diploid Cell Vaccine, Vero cell rabies vaccine, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

• Boehringer Ingelheim International GmbH
• Cadila Pharmaceuticals Limited
• Serum Institute of India Pvt. Ltd. (Cyrus Poonawalla Group)
• Elanco Animal Health, Inc.
• Zoetis, Inc.
• Merck & Co., Inc.
• Novartis AG
• Bharat Biotech Ltd.
• Sanofi S.A.
• Virbac

Market Report Segmentation

By Prophylaxis Type

• Post-exposure Prophylaxis
• Pre-exposure prophylaxis

By End User

• Hospitals
• Veterinary Clinics
• Others

By Application

• Human
• Animal

By Product Type

• Chick Embryo Cells Rabies Vaccine
• Human Diploid Cell Vaccine
• Vero cell rabies vaccine
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe